Phase I Study of BM2216 ER vs. Melogabalin Besilate: Safety, PK, and Food Effect in Healthy Adults

NCT06846567 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Neuropathies
Diabetes Mellitus

Interventions

DRUG: BM2216 Extended-Release tablets（5.5mg）
DRUG: Mirogabalin Besilate Tablets
DRUG: BM2216 Extended-Release Tablets(11mg)
DRUG: BM2216 Extended-Release Tablets(16.5mg)

Sponsor

Zhejiang Anglikang Pharmaceutical Co., Ltd.